Evidence map›Paper›PMID 32283236›Full record

ArticleJournal of the American Academy of Dermatology2020

Does hydroxychloroquine combat COVID-19? A timeline of evidence.

Erisa Alia, Jane M Grant-Kels

Abstract readLetter
In one paragraph

Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Efficacy of early use of remdesivir: a systematic review of subgroup analysis.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Pooled it
  2. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Response to: "Risks of hydroxychloroquine use for COVID-19 prophylaxis".Journal of the American Academy of Dermatology · 2020
    Article
  16. Article
  17. Risks of hydroxychloroquine use for COVID-19 prophylaxis.Journal of the American Academy of Dermatology · 2020
    Article
  18. Review
  19. Review
  20. Authors' response.The Indian journal of medical research
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Erisa AliaDermatology Department, University of Connecticut, Farmington, Connecticut.
Jane M Grant-KelsDermatology Department, University of Connecticut, Farmington, Connecticut. Electronic address: grant@uchc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BetacoronavirusCoronavirus InfectionsCOVID-19Drug ApprovalHumansHydroxychloroquinePandemicsPneumonia, ViralRandomized Controlled Trials as TopicSARS-CoV-2Time FactorsUnited StatesUnited States Food and Drug AdministrationHydroxychloroquine

Identifiers

PMID32283236
PMCPMC7151328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.